N-Acetyl Cysteine (NAC) for Immune Function

N-acetylcysteine supports immune function indirectly. It is a cysteine donor, and cysteine is the rate-limiting substrate for glutathione synthesis — the antioxidant that lymphocytes depend on to proliferate and function during an immune response. Immune cells are unusually sensitive to glutathione availability because mounting a response generates a large oxidative burden. The clinical evidence is strongest at the respiratory mucosa, where NAC's mucolytic action and its antioxidant role converge.

The best-characterised finding is a reduction in exacerbation frequency in chronic bronchitis and COPD with long-term oral NAC. There is also an older, frequently cited trial in elderly adults reporting fewer symptomatic influenza-like episodes. Taken together this supports resilience of respiratory immune defence rather than a general immune-boosting claim.

NAC is deacetylated to L-cysteine, which combines with glutamate and glycine to form glutathione. Because cysteine is the limiting step, raising its supply directly raises intracellular glutathione in lymphocytes and macrophages, protecting them from the oxidative damage generated by their own respiratory burst.

There is a second, unrelated mechanism at the airway surface. The free thiol group cleaves disulphide bonds in mucin polymers, thinning mucus and improving mucociliary clearance — a mechanical contribution to infection defence, since stagnant mucus is where bacterial colonisation takes hold. NAC also suppresses NF-kB-driven cytokine production and disrupts bacterial biofilms in vitro, which may explain part of the exacerbation reduction seen in chronic bronchitis.

Respiratory trials use 600 mg once or twice daily, with 1200 mg daily favoured in patients with more frequent exacerbations. Benefit in the exacerbation literature accrues over months of continuous use, not days, so this is a maintenance regimen rather than something to start when symptoms appear.

The linked Cochrane review of mucolytic agents versus placebo in chronic bronchitis and COPD pooled a large trial base and found that regular mucolytic use, with NAC the most studied agent, reduced the likelihood of exacerbations and days of disability, with adverse event rates similar to placebo. Cochrane also notes that effect sizes were larger in older trials than in more recent, better-controlled ones, so the realistic expectation is a modest reduction in exacerbation risk. The review addresses respiratory outcomes specifically; extending it to whole-body immune function is an inference from the shared glutathione mechanism rather than a directly tested claim.

Oral NAC is well tolerated across long-duration trials, with adverse event rates comparable to placebo. The usual complaints are gastrointestinal — nausea, heartburn, loose stools — and the sulphurous smell, which is characteristic rather than a sign of spoilage. Taking it with food reduces stomach upset.

Most NAC interactions come from its free thiol group, which is chemically reactive: it can inactivate certain drugs on contact and amplifies nitric oxide-mediated vasodilation. Separating doses solves several of these.